Thus, array-based karyotyping revealed MDS and related myeloid neoplasms with a normal karyotype to have one or more genomic abnormalities, including deletions of TET2 and RUNX1 genes (40%) [26,27,29]. This evidence concerns the gene TET2 and myelodysplastic syndrome.